dose in Medical Technology

AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product

- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer - WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administrati...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

Data Being Presented Today at 44th Annual Meeting of EASL Management to Discuss Study Results and Program Status During Q1 Financial Results Call at 5 P.M. EDT Today SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that ANA598,...

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial d...

AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints

LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline i...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today the results of a Phase I clinical trial of ANA598 in h...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

Several abstracts highlighting CIMZIA's long-term benefits and value in moderate to severe Crohn's disease patients presented at American College of Gastroenterology (ACG) ORLANDO, Fla. Oct. 7 /PRNewswire-FirstCall/ -- Data from two studies presented this week by UCB at the American College ...

Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients

GOTEBORG, Sweden, October 2 /PRNewswire/ -- Calabar AB announced today that their Phase II repeated dose study in xerostomia ("dry mouth") patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective of the study is to...

Bronchitol Cystic Fibrosis Dose Trial Results Positive

Bronchitol Demonstrates Dose-Related Improvements in Lung Function of Cystic Fibrosis Patients SYDNEY, Australia, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Speciality pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results from its Phase II tria...

New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study

Results Presented at the ADA's Annual Scientific Sessions SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the results of the dose-finding study for its new injectable diabetes compound AVE0010, a GLP-1 agonist, were presented at the American Diabetes ...

Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product

WASHINGTON, May 20 /PRNewswire-USNewswire/ -- Fuisz Tobacco today announces the results of a cross-over clinical study comparing the absorption of nicotine from the use of Fuisz Tobacco's dissolving tobacco strip and the use of a nicotine 2mg chewing gum -- the study's control. (Photo: http...

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration

International Study to Evaluate Efficacy and Safety in Treating a Leading Cause of Blindness LEVERKUSEN, Germany, MONTVILLE, New Jersey and TARRYTOWN, New York, May 8 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) tod...

Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause

-Estrogen Continues to be Gold Standard for Management of Hot Flashes- MAPLE GROVE, Minn., May 5 /PRNewswire/ -- Medical specialists from around the country will gather this week to discuss the latest research in obstetrics and gynecology, and menopause and estrogen therapy will be among the ...

Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer

BETHLEHEM, Pa., May 2 /PRNewswire/ -- Can a blood test improve treatment outcomes for colorectal cancer patients? Recently published studies indicate that personalized chemotherapy dose management -- measuring drug levels in patients' blood and adjusting them for optimal dosing -- can substant...

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

Second Phase Opens With Higher Dose Regimens SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no majo...

Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated

- Findings Support Continued Development for Chronic Pain and Non-Pain Indications - LA JOLLA, Calif., Feb. 5 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that data from its multiple dose clinical trial of tezampanel, an antagonis...

Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis

BRIDGEWATER, N.J. and CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were published this month in the January issue of the peer- reviewe...

Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)

Results Show Statistically Significant Indications of PS433540's Potential in Treating Hypertension PRINCETON, N.J., Dec. 3 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced...

Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)

Pharmacopeia Elects to Expand Study to Include 1,000 mg Dose PRINCETON, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP ), an innovator in the discovery and development of novel small molecule therapeutics, today announced that based on initial results from the Compa...

Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers

-R7128 Demonstrates Safety and Tolerability with No Clinically Significant Adverse Events- -Conference Call Scheduled for 8:30AM (ET) Today- PRINCETON, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) is presenting safety, tolerabil...

TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, ...

TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel

- Tezampanel Development Targeting Chronic Pain Conditions; Compound Currently in Phase IIb Clinical Trial for Acute Migraine - LA JOLLA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that it has initiated a Phase I multiple d...

Genetics Determine Optimal Drug Dose of Common Anticoagulant

WASHINGTON, Aug. 21 /PRNewswire-USNewswire/ -- Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology. This re...

Intermezzo(R) 3.5 mg Achieves Greater Early Bioavailability Than Ambien(R) 10 mg Despite 65% Lower Dose

Data Presented as Poster Presentation at the Associated Professional Sleep Societies 2008 Annual Meeting BALTIMORE, June 11 /PRNewswire/ -- Data was presented today at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) demonstrating that within 20 ...

Study: Identical Doses of BiDil Components Are Not Bioequivalent to the Fixed Dose Combination-BiDil-Used in A-HeFT

NEW ORLEANS, La.--(BUSINESS WIRE)--Mar 26, 2007 - A study comparing the formulations of isosorbide dinitrate (ISDN) and hydralazine (HYD) used in V-HeFT I and V-HeFT II, and BiDil, the proprietary fixed dose combination, used in the African American Heart Failure Trial (A-HeFT) demonstrated no bioe...

Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to invest...

CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced preliminary results of a phase 2 clinical trial studying CRx-139 (a synergistic combination of 3mg prednisolone and the antidepressant paroxetine) and 3mg prednisolone alone, in patients with ...

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of COPAXONE(R) given daily to the currently approved COPAXONE(R) 20 mg dose showed a 38 percent greater reduction in inflammatory disease activity as m...

Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-remitting Multiple Sclerosis (RRMS) Doubled Dose of COPAXONE Maintained Proven Safety Profile and Further Reduced Relapses and Lesions JERUSALEM, Israel, April 17, 2007 – A 9-month, rando...

Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey

MALVERN, Pa., June 15, 2007 /PRNewswire/ -- Solstice Neurosciences, Inc. today reported important results from a multicenter, forced dose escalation study of Botulinum Toxin Type B Injectable Solution (Myobloc(R)) recently presented at the 11th International Congress of The Movement Disorders Soci...

MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program at the World Asthma Meeting at the Lutfi Kirdar Convention and Exhibition Center in Istanbu...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide invest...

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality of Company's Once-Daily Tramadol to be Published in Biopharmaceutics Journal - LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will present a poster discussing the dose titration of its once-dai...

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

...tions to its patients through the addition of High dose Rate (HDR) brachytherapy. This latest advance in b...controlled delivery system is used to optimize the dose distribution to the target. As a result of this pr...and side effects may be reduced. Unlike low dose rate brachytherapy treatment, HDR therapy can be d...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... percent for placebo at six months for the highest dose tested. By comparison, the mean percent change in ...h treatment period, patients receiving the highest dose of BA058 increased lumbar spine BMD by 12.9 percen...calcemia was half that of Forteo(R) in the highest dose of BA058 tested. Radius will submit additional det...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...randomized in a one-to-one ratio to receive either 120 mg of denosumab subcutaneously every four weeks (Q4W) or Zometa administered intravenously at a dose of 4 mg single, 15 minute infusion every four weeks. In clinical trials thus far to test new medications for bone metastases, treatment succes...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...ALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been published in a leadi...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...allel-group study (n=636). All patients received a dose of 234 mg on Day 1 in the deltoid muscle. From Day... increase with the length of therapy and the total dose received. This condition can also develop after a ...le in milligrams (mg) of paliperidone palmitate in dose strengths of 39 mg, 78 mg, 117 mg, 156 mg and 234 ...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...to be active in many solid tumors in human clinical studies. Access has commenced a new clinical study of ProLindac in France. The study will examine dose levels and regimens of ProLindac monotherapy in cancer patients, provide additional data to support design of combinations studies, and extend the saf...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...d was a multicenter, randomized, double-blind, two dose study of velaglucerase alfa in patients with Type ...monstrated. The magnitude of changes in the 45U/kg dose was also clinically important, and a trend in liver volume reduction was observed. The 60U/kg dose performed numerically as well or better than 45U/k...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...study, led by Dr. J. R. Rigas, enrolled twelve patients, six to each of two dose levels. Patients were treated in 21-day cycles, with cohort one receiving 1...ood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Onc...